Carbamate stereoisomer
The compound of formula (I) is a water-stable, long acting β 2 -selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like.
1. A pharmaceutical composition comprising a compound of formula (I)
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein said pharmaceutical composition is an aqueous solution or suspension and wherein said compound of formula (I) constitutes at least 90% by weight of all carbamic acid, [2-hydroxy-5-[1-hydroxy-2-[[(2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, methyl ester present.
2. A pharmaceutical composition according to claim 1 wherein the aqueous solution or suspension is administered using a nebuliser.
3. A pharmaceutical composition comprising a compound of formula (I)
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein said pharmaceutical composition is an aerosol formulation and wherein said compound of formula (I) constitutes at least 90% by weight of all carbamic acid, [2-hydroxy-5-[1-hydroxy-2-[[(2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, methyl ester present.
4. A pharmaceutical composition according to claim 3 wherein the compound of formula (I) is in solution.
5. A pharmaceutical composition according to claim 4 further comprising at least one co-solvent or solubilizing agent.
6. A pharmaceutical composition according to claim 5 wherein said co-solvent or solubilizing agent is selected from glycerol and ethanol.
7. A pharmaceutical composition according to claim 3 further comprising at least one propellant.
8. A pharmaceutical composition according to claim 3 further comprising at least one surfactant suitable for use in aerosol formulations.
9. A pharmaceutical composition according to claim 8 wherein the surfactant is present in an amount between 1:100 to 1:10 surfactant:compound of formula I.
10. A pharmaceutical composition according to claim 8 wherein the surfactant is oleic acid.
11. A pharmaceutical composition of claim 3 further comprising a propellant, a surfactant and an optional co-solvent or solubilizing agent.
12. A pharmaceutical composition comprising a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein said pharmaceutical composition is in the form of a dry powder and wherein said compound of formula (I) constitutes at least 90% by weight of all carbamic acid, [2-hydroxy-5-[1-hydroxy-2-[[(2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, methyl ester present.
13. A pharmaceutical composition according to claim 12 comprising crystals of formula I.
14. A pharmaceutical composition according to claim 13 wherein the crystals have a mass median aerodynamic diameter of from 1 to 10 microns.
15. A pharmaceutical composition according to claim 13 further comprising a pharmaceutically acceptable carrier.
16. A pharmaceutical composition according to claim 15 wherein the pharmaceutically acceptable carrier is selected from a monosaccharide, disaccharide, trisaccharide, oligosaccharide, polysaccharide, polyol, amino acid and protein, optionally in the form of an pharmaceutically acceptable ester, acetal, hydrate or salt.